In Practise Logo
In Practise Logo - Blue
In Practise Logo
IP Interview
Published November 19, 2020

Illumina: Grail Acquisition & Early Cancer Detection

ILMNIllumina
Executive Bio

Shilpen Patel

Former Medical Director at GRAIL

Why is this interview interesting?

  • Walk through the process of GRAIL’s CCGA clinical trial
  • How GRAIL detects for cancer versus Freenome and Thrive
  • The three different assays GRAIL tested that led to the Galleri test product
  • Trade offs between specificity and sensitivity
  • How to interpret the clinical trial results
  • How GRAIL uses data and machine learning to analyze results

Interview Transcript

Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.

This is a snippet of the transcript.to get full access.

Free Sample of 50+ Interviews

Sign up to test our content quality with a free sample of 50+ interviews.

Or contact sales for full access
Already have an account? Sign in

Related Content

Bio-Rad: Switching Costs and Competitive Dynamics in Single-Cell & Digital PCR

Former Director at Bio-Rad Laboratories

Vitrolife: Genetic Testing Lab Operations

Former Senior Scientific Executive at Igenomix

10x Genomics: Visium, NanoString Tech & Future of Single-Cell Analysis

Former Sales Manager at 10x Genomics

Weekly Update: Ashtead & Equipment Rental: A More Resilient Business

© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.